The majority of patients with breast cancer have hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative disease, and nearly 30% of patients initially diagnosed with early-stage breast cancer will ultimately develop metastatic breast cancer (mBC).1 This evidence concerns the gene ERBB2 and breast carcinoma.